FRX.TO
Fennec Pharmaceuticals Inc. [FRX.TO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
FRX.TO Stock Summary
Top 10 Correlated ETFs
FRX.TO
Top 10 Correlated Stocks
FRX.TO
In the News
FRX.TO Financial details
Company Rating
-
Market Cap
394.03M
Income
-16.07M
Revenue
21.25M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-13.91
Forward P/E
-
PEG
3.17
P/S
21.7
P/B
-26.71
P/C
-
P/FCF
-13.27
Quick Ratio
4.33
Current Ratio
4.84
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.51
EPS next Y
-
EPS next Q
-
EPS this Y
-34.07%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
49.42%
EPS Q/Q
-
-
-
-
-
SMA20
-22.22%
SMA50
-22.22%
SMA100
-12.5%
Inst Own
-
Inst Trans
-
ROA
-106%
ROE
268%
ROC
-1.14%
Gross Margin
96%
Oper. Margin
-131%
Profit Margin
-155%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.27-15.43
52W High
-52.8%
52W Low
-21.33%
RSI
32
Rel Volume
0.01
Avg Volume
324
Volume
2
Perf Week
0%
Perf Month
-25.32%
Perf Quarter
3.21%
Perf Half Y
8.09%
-
-
-
-
Beta
0.4
-
-
Volatility
0%, 1.04%
Prev Close
0%
Price
7.08
Change
0%
Something similar
Company Profile
- Volume Average 324
- Market Capitalization 394.03M
- Employee 29
- CEO Mr. Rostislav Raykov
- Headquarters Research Triangle Park,NC,US
- IPO Date 2001-06-12
-
Website
https://www.fennecpharma.com 
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
